Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...

Investing.com -- Shares of vTv Therapeutics Inc . (NASDAQ: VTVT) rose 15% after the company announced that the FDA has lifted the clinical hold on its Cadisegliatin program for diabetes. Trading had ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...

A new study has found that the diabetes drug tirzepatide helps people lower their blood sugar and lose weight more quickly ...

A Newsom 2028 presidential run may be in the works based on the California governor's recent moves, but his failures could haunt a future White House bid.

Dr. Marty Makary, Trump's nominee for FDA Commissioner, breezed through his confirmation hearing despite tough questions from Democrats and Republicans.

(CNN) — President Donald Trump’s pick to lead the US Food and Drug Administration told senators in a tense ... of these diseases – general body inflammation and generalized insulin resistance – and ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

California’s low-cost insulin plan is more than a year behind schedule with no clear timeline. Advocates say the delay is ...